Is CAR‑T cell therapy effective for glioblastoma?

CAR-T Cell Therapy for Glioblastoma: Investigational with Early Promise but Not Yet Standard of Care

CAR-T cell therapy for glioblastoma is currently investigational and should only be offered within clinical trials, as it has not demonstrated sufficient efficacy to be recommended as standard treatment outside of research settings 1.

Current Evidence Status

The most recent ASCO-SNO guidelines (2022) for glioblastoma management do not include CAR-T therapy as a recommended treatment option 1. For recurrent glioblastoma specifically, the guidelines explicitly state that patients should be referred for participation in clinical trials where possible, acknowledging that no therapy has clearly demonstrated superior activity in the recurrent setting 1.

Early Clinical Trial Results Show Feasibility but Limited Durability

Recent phase I trials have established important proof-of-concept findings:

• Safety and feasibility: Intracranial CAR-T cell delivery appears safe with doses up to 2.5 × 10⁷ cells well-tolerated 2
• Transient responses: The anti-IL13Rα2 CAR-T trial (NCT02208362) in 65 patients showed a 50% disease-control rate and 23% one-year survival 3
• Early bioactivity: Multiple trials targeting EGFR family antigens, IL13Rα2, HER2, EGFRvIII, EphA2, B7-H3, and GD2 have demonstrated transient radiological responses 2, 4
• Limited durability: Responses have been rapid but transient across studies, with 56 of 128 patients showing at least some measure of response 2

Key Limitations Preventing Clinical Adoption

The technology faces several critical barriers that explain why it remains investigational:

• Antigen heterogeneity: Glioblastoma's molecular diversity leads to antigen-negative escape 4
• Immunosuppressive tumor microenvironment: The GBM microenvironment actively suppresses CAR-T cell function 4, 5
• Limited CNS trafficking: Restricted immune cell movement across the blood-brain barrier 5
• Lack of durable responses: Initial tumor control does not translate to sustained benefit 3, 2

Clinical Recommendation Algorithm

For newly diagnosed glioblastoma: Follow standard ASCO-SNO guidelines with radiation plus concurrent and adjuvant temozolomide 1. CAR-T therapy has no role in this setting.

For recurrent glioblastoma:

1. Assess clinical trial eligibility first 1
2. If CAR-T trial available and patient meets criteria, refer for enrollment
3. If no trial access, consider standard options: bevacizumab (FDA-approved, PFS benefit only), lomustine, or re-challenge with temozolomide 1

Important Caveats

The heterogeneous reporting of outcomes across CAR-T trials makes efficacy comparisons difficult 2. While newer approaches using multi-antigen targeting and locoregional delivery aim to address resistance mechanisms 4, these remain experimental. The most recent trials (2024-2026) continue to report only phase I data focused on safety and feasibility rather than definitive efficacy 3, 2, 6, 7, 8.

Do not offer CAR-T therapy outside of formal clinical trials, as the evidence does not support its use as standard treatment and patients may miss opportunities for established therapies or better-designed trials.